title: [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
abstract: OBJECTIVE
  To establish a nude mouse model of malignant ascites with human ovarian carcinoma cell line OVCAR3 which highly expresses VEGF and evaluate the therapeutic of Avastin combined with cisplan.
  
  
  METHODS
  Forty-eight nude mice with malignant ascites resulting from intraperitoneal transplantation of human ovarian carcinoma cell line OVCAR3 were treated with intraperitoneal injection of Avastin, cisplan, their combination, and PBS, respectively, to observe the effect on ascites development, VEGF content in the ascites, peritoneal permeability, development of new vessels and number of tumor cells in the ascites.
  
  
  RESULTS
  Avastin obviously inhibited ascites accumulation and peritoneal capillary permeability, reduced VEGF protein level and microvascular density in the tumor tissues and the number of red cells and tumor cells in the malignant ascites, and prolonged the survival of the mice. The combination of Avastin and cisplan further enhanced the therapeutic efficacy of Avastin.
  
  
  CONCLUSIONS
  The bio-chemotherapeutic strategy with Avastin combined with cisplan can be a promising method for treatment of malignant ascites.
authors.affiliation: Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. cyj7728 @163.com
authors.forename: Yan-jun
authors.initials: YJ
authors.lastname: Cai
authors.forename: Da-yong
authors.initials: DY
authors.lastname: Zheng
authors.forename: Rong-cheng
authors.initials: RC
authors.lastname: Luo
authors.forename: Jin-zhang
authors.initials: JZ
authors.lastname: Chen
authors.forename: Ai-ming
authors.initials: AM
authors.lastname: Li
authors.forename: Jing-le
authors.initials: JL
authors.lastname: Xi
authors.forename: Xue-mei
authors.initials: XM
authors.lastname: Ding
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001201:Ascites / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D000068258:Bevacizumab; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage; D004357:Drug Synergism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000150:complications* / Q000235:genetics / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D002945:Cisplatin